Natera Stock Volume Surges to $434 Million Despite Two-Day Decline

On May 30, 2025, Natera (NTRA) experienced a significant trading volume of $434 million, marking a 64.12% increase from the previous day. However, the stock price declined by 0.20%, marking the second consecutive day of decline, with a total decrease of 2.16% over the past two days.

Natera's stock has been under pressure due to a downgrade from StockNews.com, which changed its rating from "hold" to "sell" in a research report released on May 19, 2025. This negative sentiment has contributed to the recent decline in the stock price.

In its first quarter of 2025, Natera reported a net loss of $66.9 million, equivalent to a loss of 50 cents per share. This financial performance has raised concerns among investors about the company's profitability and future prospects.

Despite the recent setbacks, Natera continues to make strides in the field of precision medicine. The company announced that it will present data from over 25 Signatera studies at the 2025 ASCO Annual Meeting, highlighting its commitment to advancing cancer research and treatment.

Additionally, Natera's Prospera Heart test has shown promising results in detecting allograft rejection, as published in the American Journal of Transplantation. This development underscores the company's leadership in cell-free DNA and genetic testing technologies.